000			02155 a2200577 4500
005			20250516163231.0
264		0	_c20131212
008			201312s 0 0 eng d
022			_a1538-7445
024	7		_a10.1158/0008-5472.CAN-13-1191 _2doi
040			_aNLM _beng _cNLM
100	1		_aGarrett, Joan T
245	0	0	_aCombination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. _h[electronic resource]
260			_bCancer research _cOct 2013
300			_a6013-23 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal, Humanized _xpharmacology
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aBreast Neoplasms _xmetabolism
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aClass I Phosphatidylinositol 3-Kinases _xantagonists & inhibitors
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoblotting
650	0	4	_aImmunoprecipitation
650	0	4	_aLapatinib
650	0	4	_aMice
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProtein Multimerization _xdrug effects
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aQuinazolines _xpharmacology
650	0	4	_aReceptor, ErbB-2 _xantagonists & inhibitors
650	0	4	_aReceptor, ErbB-3 _xantagonists & inhibitors
650	0	4	_aSignal Transduction
650	0	4	_aSurvival Rate
650	0	4	_aTrastuzumab
650	0	4	_aTumor Cells, Cultured
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aSutton, Cammie R
700	1		_aKurupi, Richard
700	1		_aBialucha, Carl Uli
700	1		_aEttenberg, Seth A
700	1		_aCollins, Scott D
700	1		_aSheng, Qing
700	1		_aWallweber, Jerry
700	1		_aDefazio-Eli, Lisa
700	1		_aArteaga, Carlos L
773	0		_tCancer research _gvol. 73 _gno. 19 _gp. 6013-23
856	4	0	_uhttps://doi.org/10.1158/0008-5472.CAN-13-1191 _zAvailable from publisher's website
999			_c22979003 _d22979003